Skip to main content

Table 2 Characteristics of continuous venovenous haemofiltration with citrate

From: Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study

 

Survivors

Non-survivors

P

n = 39

n = 58

Blood flow (ml/min)

180 ± 0

180 ± 0

1.00

Substitution flow (ml/h)

2403 ± 16

2397 ± 59

0.54

Prescribed dose (ml/kg//h)

24 ± 4

26 ± 6

0.13

Filter life (h)

38 ± 24

23 ± 20

0.004

Reasons for termination (%)

  

0.05

   Clotting

41

47

   Transfer to OR/radiology

13

4

   Renal function recovery

24

9

   Death of patient

0

14

   Elective change

15

10

   Citrate toxicity

1

7

   Miscellaneous

6

13

Citrate accumulation

1

8

0.04

Changes in calcium infusion pump rate,

day 1

2.2 ± 1.3

2.2 ± 1.5

0.99

day 2

1.6 ± 1.6

2.0 ± 2.0

0.37

day 3

1.5 ± 1.4

1.6 ± 1.2

0.70

day 5

1.6 ± 1.3

1.2 ± 1.1

0.99

day 7

1.9 ± 1.5

1.1 ± 1.1

0.18

Duration of CVVH (h)

219 ± 237

223 ± 507

0.96

  1. Data are expressed as mean (± standard deviation) or number of patients where appropriate; CVVH: continuous venovenous haemofiltration.